Abbott Named One of the Best Companies for Hispanics by Hispanic Business Magazine

AbbottAbbott has been named to Hispanic Business magazine's list of the nation's best companies for Hispanics. Abbott was recognized as one of the magazine's "Diversity Elite 60" companies for its commitment to Hispanic hiring, promotion, marketing, philanthropy and supplier diversity.

"As an innovation-driven company, Abbott relies on the diversity of our people to provide different ideas, perspectives and experience that enable us to translate science into new solutions for patients," said Stephen Fussell, senior vice president, Human Resources, Abbott.

Diversity a Long-Standing Priority for Abbott
Abbott's commitment to diversity starts at the top with the company's Chairman and Chief Executive Officer Miles D. White, who chairs the company's Executive Inclusion Council. The Council oversees the company's diversity and inclusion efforts, monitors the hiring and advancement of women and minorities in management, and supports programs that promote an inclusive work environment for all employees.

Abbott maintains aggressive goals for the recruitment, hiring and retention of women and minorities. Minorities at Abbott make up more than one-quarter (26 percent), and women nearly one-half (47 percent), of Abbott's total U.S. workforce. Abbott has increased the number of minorities in management by 68 percent and the number of women in management by 64 percent over the past five years.

More than 7,700 employees participate in Abbott's employee networks, which play a vital role in building more diverse leadership within Abbott. These include: LA VOICE Network (Hispanic/Latino), Women Leaders in Action, Black Business Network, Asian Cultural Leadership Network, PRIDE Network gay/lesbian) and the Part-Time Network. By focusing on career development, mentoring, informal networking and work-life integration, Abbott's active networks offer leadership and expanded advancement opportunities for women and minorities. Each network is sponsored by a member of senior management who helps align the group's objectives with Abbott's business strategy.

Abbott Widely Recognized as a Premier Employer
In addition to being included in Hispanic Business magazine's "Diversity Elite 60," Abbott has been included on DiversityInc magazine's list of the "Top 50 Companies for Diversity" for four years. The company was named one of the "Top 50 Companies for Black MBAs to Work" by Black MBA magazine, and has been recognized for many years by FORTUNE magazine as one of the "Best Companies for Minorities."

Abbott also has been included in Working Mother magazine's "100 Best Companies for Working Mothers" for the past seven years, has been named one of the "50 Best Places to Launch a Career" by BusinessWeek and was included in the 2008 edition of the Princeton Review's Best Entry-Level Jobs. In addition, Abbott has been recognized by Science and The Scientist magazines as a top employer for scientists, and FORTUNE has named Abbott as one of "America's Most Admired Companies" every year since the list's inception in 1983.

About Abbott
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...